Emerging oligonucleotide therapeutics for rare neuromuscular diseases

Emerging oligonucleotide therapeutics for rare neuromuscular diseases

Research and drug development concerning rare diseases are at the cutting edge of scientific technology. To date, over 7,000 rare diseases have been identified. Despite their individual rarity, 1 in 10 individuals worldwide is affected by a rare condition. For the majority of these diseases, there i...

Полное описание

Библиографические подробности
Главные авторы:	Aoki, Y, Wood, MJA
Формат:	Journal article
Язык:	English
Опубликовано:	IOS Press 2021

Схожие документы

Oligonucleotide-based therapies for neuromuscular disease
по: Douglas, A, и др.
Опубликовано: (2015)

Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases
по: Tsoumpra, MK, и др.
Опубликовано: (2019)

Advances in oligonucleotide drug delivery
по: Roberts, TC, и др.
Опубликовано: (2020)

Recent advances in antisense oligonucleotide therapy in genetic neuromuscular diseases
по: Ashok Verma
Опубликовано: (2018-01-01)

Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment
по: Gait, M, и др.
Опубликовано: (2018)

Antisense Oligonucleotide Gene Therapy for Neuromuscular Disorders
по: Ryan Gotesman
Опубликовано: (2018-11-01)

Development of LNA gapmer oligonucleotide-based therapy for ALS/FTD caused by the C9orf72 repeat expansion
по: Sathyaprakash, C, и др.
Опубликовано: (2020)

Antisense oligonucleotides and their applications in rare neurological diseases
по: Simon McDowall, и др.
Опубликовано: (2024-09-01)

Oligonucleotides-Based Therapeutics
по: Bernard Lebleu
Опубликовано: (2021-09-01)

Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases
по: Marafini I, и др.
Опубликовано: (2020-06-01)

Challenges for antisense oligonucleotide-based therapeutics, in particular for exon 51-skipping in Duchenne muscular dystrophy
по: Aoki, Y, и др.
Опубликовано: (2011)

Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis
по: Christoph Niemietz, и др.
Опубликовано: (2015-09-01)

Delivery of therapeutic oligonucleotides in nanoscale
по: Lei Wu, и др.
Опубликовано: (2022-01-01)

Fine tuning of phosphorothioate inclusion in 2'-O-methyl oligonucleotides contributes to specific cell targeting for splice-switching modulation
по: Aoki, Y, и др.
Опубликовано: (2021)

Immortalized canine dystrophic myoblast cell lines for development of peptide-conjugated splice-switching oligonucleotides
по: Tone, Y, и др.
Опубликовано: (2021)

The endosomal escape vehicle platform enhances delivery of oligonucleotides in preclinical models of neuromuscular disorders
по: Xiang Li, и др.
Опубликовано: (2023-09-01)

Mesyl phosphoramidate backbone modified antisense oligonucleotides targeting miR-21 with enhanced in vivo therapeutic potency
по: Patutina, OA, и др.
Опубликовано: (2020)

Splicing therapy for neuromuscular disease.
по: Douglas, A, и др.
Опубликовано: (2013)

The role of chemistry in the success of oligonucleotides as therapeutics
по: Pawan Kumar, и др.
Опубликовано: (2022-02-01)

TRIM32 and Malin in Neurological and Neuromuscular Rare Diseases
по: Lorena Kumarasinghe, и др.
Опубликовано: (2021-04-01)

Selective Neuromuscular Denervation in Taiwanese Severe SMA Mouse Can Be Reversed by Morpholino Antisense Oligonucleotides.
по: Te-Lin Lin, и др.
Опубликовано: (2016-01-01)

Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases
по: Xue, K, и др.
Опубликовано: (2020)

Short G-rich oligonucleotides as a potential therapeutic for Huntington's Disease
по: Parekh-Olmedo Hetal, и др.
Опубликовано: (2006-10-01)

Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease
по: Davide Di Fusco, и др.
Опубликовано: (2019-03-01)

Covalently attached intercalators restore duplex stability and splice-switching activity to triazole-modified oligonucleotides
по: Dysko, A, и др.
Опубликовано: (2022)

Targeting RNA to treat neuromuscular disease.
по: Muntoni, F, и др.
Опубликовано: (2011)

Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape
по: Wood, M, и др.
Опубликовано: (2017)

Neuromuscular disorders: therapeutic advances.
по: Talbot, K
Опубликовано: (2007)

Delivery of oligonucleotide‐based therapeutics: challenges and opportunities
по: Hammond, SM, и др.
Опубликовано: (2021)

Amphiphilic Oligonucleotide Derivatives—Promising Tools for Therapeutics
по: Irina A. Bauer, и др.
Опубликовано: (2024-11-01)

Delivery of oligonucleotide‐based therapeutics: challenges and opportunities
по: Suzan M Hammond, и др.
Опубликовано: (2021-04-01)

Peptide–Oligonucleotide Conjugation: Chemistry and Therapeutic Applications
по: Anna L. Malinowska, и др.
Опубликовано: (2024-09-01)

Nonviral delivery systems for antisense oligonucleotide therapeutics
по: Si Huang, и др.
Опубликовано: (2022-09-01)

Chemistry of Therapeutic Oligonucleotides That Drives Interactions with Biomolecules
по: Chisato Terada, и др.
Опубликовано: (2022-11-01)

Oligonucleotide Therapeutics: From Discovery and Development to Patentability
по: Lara Moumné, и др.
Опубликовано: (2022-01-01)

Mesyl phosphoramidate oligonucleotides as potential splice-switching agents: impact of backbone structure on activity and intracellular localization
по: Hammond, SM, и др.
Опубликовано: (2021)

Improving translational studies: lessons from rare neuromuscular diseases
по: Dominic Wells
Опубликовано: (2015-10-01)

Therapeutic approaches for Duchenne muscular dystrophy
по: Roberts, TC, и др.
Опубликовано: (2023)

Regeneration mechanisms and therapeutic strategies for neuromuscular junctions in aging and diseases
по: Masashi Fujitani, и др.
Опубликовано: (2025-01-01)

Editorial: Diagnosis, animal models and therapeutic interventions for neuromuscular diseases
по: Muthukumar Karuppasamy, и др.
Опубликовано: (2024-09-01)